Findings from District Hospital Advance Knowledge in Disease Progression (Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland).

A recent study conducted in Poland analyzed the adverse events experienced by renal cell carcinoma patients undergoing combined immunotherapy with nivolumab and ipilimumab. The research found that immune-related adverse events (irAEs) were associated with a lower risk of disease progression and a higher disease control rate. However, patients who experienced hepatotoxicity had poorer outcomes, with a greater risk of death. The study suggests that irAEs could potentially serve as a predictive factor for the efficacy of this immunotherapy regimen in treating renal cell carcinoma. [Extracted from the article]